Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
Sponsor: Tianjin Medical University General Hospital
Summary
Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes without effective pharmacological treatment. Inflammation following ICH contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. Preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (HSPCs) are swiftly activated after ICH. Thereafter, these HSPCs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. Stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. This study is to assess the safety and efficacy of a β3 adrenergic receptor agonist Mirabegron as a potential treatment option in ICH patients.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2024-01-17
Completion Date
2026-11-10
Last Updated
2025-05-28
Healthy Volunteers
No
Conditions
Interventions
Standard treatment+mirabegron
In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.
Standard treatment
Standard treatment
Locations (1)
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China